ENDURING - 14TH ANNUAL NORTH CAROLINA RESEARCH TRIANGLE PULMONARY HYPERTENSION SYMPOSIUM
This one-day symposium will focus on fortifying the knowledge base of physicians and other allied health professionals involved in diagnosing and treating Pulmonary Arterial Hypertension, keeping them abreast of the ever-changing diagnostic and treatment paradigms. The symposium will address issues as it relates to appropriate diagnostic procedures, proper treatment choices, and timing of referral for more advanced care to pulmonary hypertension centers for healthcare providers at the front lines of screening for and diagnosing Pulmonary Arterial Hypertension (PAH). It will also address consideration of lung transplant when therapies are inadequate.
- Allied Health Professionals
- Nurse Practitioners
- Physician Assistants
- Describe classification of Pulmonary Hypertension, according to the World Symposium classifications and including updates from the 6th World Symposium, as well as the treatment options with respect to PAH-specific therapies.
- Recognize and distinguish similar disease processes that may or may not respond to Pulmonary Arterial Hypertension specific therapy. (These in part include PH associated with congenital heart disease, parenchymal lung disease, left heart and lung disease as well as liver disease. Cases will afford examples to think about the intracacies of these issues in patient care.)
- Congenital Heart disease associated PAH is part of the WHO Group 1 classification. Recognize treatment and care specific to this population.
- WHO Group 3 Pulmonary Hypertension related to lung disease is undergoing resurgence of interest. Explain who is a candidate for therapy and when to initiate.
- Up to 70% of people with pulmonary arterial hypertension are women. Describe the differences in gender in terms of risk, and response to therapy.
- While we are fortunate to have available multiple medications over the last 10 to 20 years, the treatments options have become more complex. Discuss combination therapy and changing therapies in response to Insurance pressures, lack of efficacy, and side effects.
- Pulmonary arterial hypertension is a progressive disease and it is imperative to continually assess disease progression and risk stratification. Examine risk Calculators and profiles to help initiate ideal up front therapy and further adjust medications throughout the care period.
- Pulmonary arterial hypertension is treatable but not curable at this time. New medications and pathways are actively being investigated for use in pulmonary arterial hypertension. Recognize these newer medications/pathways and applications of these.
- Lung Transplantation/Heart-Lung transplantation is used when PH meds fail. Explain which patients are candidates and the time frame to consider this option. Describe pre- and peri-transplant process.
- Terry Fortin, MD
Course Director, Speaker
- H. James Ford, MD
Course Director, Speaker
- Sudarshan Rajagopal, MD
- Lisa Rose-Jones, MD
- Aimee Lou Babeira, RN
- Laura Nowicki, RN
- Jordan Whitson, MD
- Rebecca Richard, PharmD
- Barbara LeVarge, MD
- Mazen Al-Qadi, MD
- Erika Berman-Rosenzweig, MD
- Tim Lahm, MD
- Nick Hill, MD
- Oksana Shlobin, MD
- ACPE - Pharmacist
- AMA PRA Category 1 Credit(s)
- 6.00 ACPE - Pharmacist
- 6.00 AMA PRA Category 1 Credit(s)™
- 6.00 ANCC
- 6.00 Attendance
- 6.00 IACET CEU
- 6.00 JA Credit - AH
- 6.00 Approved for AMA PRA Category 1 Credit(s)™